The Pulmonary Fibrosis Community Again Commends The Pulmonary Fibrosis
Foundation's Biennial PFF Summit
CHICAGO, Dec. 17, 2013
PFF Summit 2013: An Environment to Improve Education, Facilitate Research, and
Increase Disease Awareness
CHICAGO, Dec. 17, 2013 /PRNewswire-USNewswire/ --The Pulmonary Fibrosis
Foundation (PFF) presented its second biennial healthcare conference, PFF
Summit 2013: From Bench to Bedside, in La Jolla, California, from December
5-7, 2013. The innovative conference brought together medical professionals,
patients, and caregivers for a three-day meeting. Over 520 people, including
individuals from 16 countries, attended the PFF Summit 2013. Gregory P.
Cosgrove, MD, Summit Co-Chair and PFF Medical Advisory Board Member, commented
on the importance of the conference: "Once again the Pulmonary Fibrosis
Foundation brought together all facets of the pulmonary fibrosis community to
collaborate, educate, and inspire; it was a truly remarkable meeting."
An outstanding international faculty presented lectures, participated in panel
discussions, and conducted question and answer sessions. "I am thankful to all
of the Summit faculty who contributed to making the PFF Summit 2013 a success.
They helped create thought-provoking and educational dialogues that we need in
order to develop better therapies," remarked Patricia J. Sime, MD, Summit
Co-Chair and PFF Medical Advisory Board Member.
The PFF partnered with National Jewish Health to provide this unique
continuing medical education (CME) program. Scientific sessions included
presentations on lung injury and repair, genetics and biomarkers, and drug
development. Some of the topics discussed during the clinical sessions were:
difficulties in making a confident diagnosis, what are the available treatment
options, how to treat co-morbidities, and effectively communicating with
patients and caregivers. The session concluded with an update on global
perspectives and ongoing clinical trials.
Concurrently a program took place for patients, family members, and caregivers
to address their educational needs as well a discussion on how to live better
with pulmonary fibrosis. All sessions will soon be available as webinars on
the Foundation's website at www.pffsummit.org.
"PFF Summit 2013 brings value to all members of the PF community – as an
educational resource, as a catalyst for change, and as a symbol of hope," said
Martin Kolb, MD, PhD, Summit Co-Chair. "It was a great opportunity to help
plan this type of a meeting where healthcare professional, researchers, and
patients attended. It was extraordinary to see it in action."
The Summit "kicked-off" with a Welcome Reception and Poster Presentations on
Thursday evening, December 5. Posters were submitted from both academic
institutions and the pharmaceutical industry. There was much new research
contained in the posters. All who attended the reception were quite impressed
with the originality and quality of the posters. The first place poster award
went to Andrew Bryant, MD, of Vanderbilt University, for his presentation on
"Endothelial Specific Inhibition of Hypoxia-Inducible Factor Blocks
Development of Pulmonary Hypertension Associated With Lung Fibrosis." The top
poster awardees were able to present their research during the Saturday
The keynote address, "Cystic Fibrosis Therapeutic Development: A Game
Changer," was given by Robert Beall, PhD, President and CEO of the Cystic
Fibrosis Foundation. Dr. Beall discussed some of the drug innovations that
have dramatically improved the lives of individuals with cystic fibrosis.
Friday also featured a special luncheon presentation by John F. Crowley,
Chairman and CEO of Amicus Therapeutics, titled "When Advocacy Research is
Personal: The Importance of Advocacy in Drug Development and Innovation." His
experience with his children's diagnosis of Pompe disease, and his unrelenting
pursuit to help them, profoundly inspired the audience.
All attendees were invited to a Networking Dinner on Friday, December 6. The
evening's highlight was an announcement from Daniel M. Rose, MD, the PFF's CEO
and Chairman of the Board, that the Foundation will commence the PFF Care
Center Network and PFF Patient Registry. This initiative should improve the
health and quality of life of patients with pulmonary fibrosis. In addition,
it will help provide critical insights that will enable the research community
to develop more effective therapies. "To make progress with this disease, we
need a multidisciplinary approach by teams of expert medical professionals, we
need more data, and we need to track the natural history of the disease," said
Dr. Rose. "The Care Center Network and Patient Registry will provide the
framework for improved patient care and progress towards a cure."
The Networking Dinner also featured speeches by representatives from the
Summit's two lead sponsors InterMune and Boehringer Ingelheim. The program
closed with the PFF's Patti Tuomey, EdD, President and Chief Operating
Officer, leading a toast thanking the faculty, sponsors, participants, and PF
community for their dedication and support.
The Pulmonary Fibrosis Foundation would like to thank the following sponsors
for their generous support; Everest Sponsors: InterMune and Boehringer
Ingelheim; Shasta Sponsor: Genentech; Grand Teton Sponsors: Biogen/Idec,
Stromedix, PatientsLikeMe, and Inspire; and Friends of the PFF Sponsors: Mike
and Donna Henderson, ImmuneWorks, and the Phyllis Dirks Demont Trust.
PFF Summit 2015: From Bench to Bedside will be held November 12-14, 2015.
Information about PFF Summit 2015 will soon be available at www.pffsummit.org.
About the Pulmonary Fibrosis Foundation
The mission of the Pulmonary Fibrosis Foundation (PFF) is to help find a cure
for idiopathic pulmonary fibrosis (IPF), advocate for the pulmonary fibrosis
community, promote disease awareness, and provide a compassionate environment
for patients and their families. The PFF collaborates with physicians,
organizations, patients, and caregivers worldwide. PFF Summit 2015: From Bench
to Beside, the PFF's third biennial international scientific conference, will
be held November 12-14, 2015. For more information visit
www.pulmonaryfibrosis.org or call 888.733.6741 or +1 312.587.9272 from outside
of the US.
About Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a condition in which over a period of
time the lung tissue becomes thickened, stiff, and scarred. The development of
the scar tissue is called fibrosis. As the lung tissue becomes scarred and
thicker, the lungs lose their ability to transfer oxygen into the bloodstream.
As a result, the brain and other organs don't receive the oxygen they need. In
some cases, doctors can determine the cause of the fibrosis, but in most
cases, there is not a known cause. When there is no known etiology for the
fibrosis (and certain pathologic or radiographic criteria are met), the
disease is called idiopathic pulmonary fibrosis or IPF. IPF affects
approximately 200,000 individuals in the United States (US), and 38,000
individuals in the European Union (EU). The annual mortality is estimated to
be 40,000 in the US alone, with an average survival of 2–3 years following
diagnosis. There is no cure for IPF. There is no FDA-approved treatment for
IPF in the US and limited therapeutic options available for individuals with
mild-to-moderate IPF in the EU, Canada, and Asia.
Contact: Cara Schillinger
Associate Vice President, Marketing and Communications
SOURCE The Pulmonary Fibrosis Foundation
Press spacebar to pause and continue. Press esc to stop.